Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Johnson & Johnson : FDA Approves J&J's Drug for Tough-to-Treat Tuberculosis

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/31/2012 | 08:19pm CET

--FDA approves J&J's Sirturo but requires prominent warning label

--Drug is unlikely to be a big moneymaker but may accrue goodwill to J&J

--Fewer than 100 Americans suffer from the disease, multidrug resistant TB

(Adds details on safety risks in paragraph eight, and comments from consumer group Public Citizen and FDA official in paragraphs 13-16.)

 
   By Joseph Walker and Nathalie Tadena 
 

The U.S. Food and Drug Administration approved Johnson & Johnson's (JNJ) drug to treat a form of resistant tuberculosis that is uncommon in the U.S. but growing globally.

The drug, Sirturo, will treat patients with multidrug resistant tuberculosis, or MDR-TB, a possibly fatal disease that affects as many as 630,000 people world-wide who can't be cured with existing therapies alone. Tuberculosis is a bacterial infection that mostly involves the lungs.

Sirturo, also known as bedaquiline, is not expected to be a large moneymaker for Johnson & Johnson (JNJ), one of the world's largest health-care conglomerate, because the disease is prevalent in poorer countries unable to afford high prices for the treatment. Providing the drug, though, could help the company create goodwill among regulators, governments and patients around the world.

"The commercial opportunity is very limited," said Pamela Van Houten, a J&J spokesperson. "This is part of our commitment to advance innovative medicines that help address serious public health issues."

The company said it expects to begin selling Sirturo in the second quarter of 2013, and won't announce its sales price until then. Fewer than 100 Americans have MDR-TB, according to J&J, but FDA approval is likely to strengthen the chances for approval in regions where the disease is more prevalent, including India, China and Eastern Europe.

However, the drug's potential side effects, including an increased risk of death, has raised concerns among members of the FDA. The agency will require that a prominent warning label be placed on the drug, informing consumers that patients taking Sirturo in clinical trials saw increased rates of fatalities.

"Because the drug also carries some significant risks, doctors should make sure they use it appropriately and only in patients who don't have other treatment options," said Edward Cox, an FDA official.

About 11.4% of patients taking Sirturo died in during clinical trials, compared to 2.5% taking placebos.

The FDA granted Sirturo accelerated approval, which is a type of temporary approval for diseases that don't have viable treatment options, based on less clinical data than required for traditional drug approvals.

The accelerated approval was based on data from a pair of Phase 2 studies--one of which showed 77.6% of patients in the treatment group reaching treatment success after 24 weeks compared with 57.6% of those in the placebo group.

It is still unclear, though, whether Sirturo caused the increase death rate, said Mel Spigelman, chief executive of the Global Alliance for TB Drug Development, which is partnering with J&J to develop Sirturo in more common strains of tuberculosis.

"It looked more likely that this was just a bad coincidence," Dr. Spigelman said. "But you have to be careful, and the monitoring will have to be rigorous."

Last month, an FDA panel supported a type of early approval for J&J's experimental drug; however, panel members were divided on whether Sirturo played a role in deaths seen in clinical studies.

"A greater number of deaths in the bedaquiline arm is concerning," FDA Deputy Director of Anti-Infective Products, said in a presentation to the panel. "The role of bedaquiline in deaths where hepatoxocity and cardiac failure are contributory could not be ruled out."

The consumer group Public Citizen, which had been strongly opposed to approval, said Monday that it was disappointed in the FDA's decision.

"There were five times more deaths in the drug group than in the placebo group," said Sidney Wolfe, director of health research at Public Citizen. "I don't see how [the FDA] can be so dismissive about it."

Tuberculosis usually is treated with a combination of four drugs for at least six months, according to the National Heart, Lung and Blood Institute. Some forms of tuberculosis, however, can't be treated with currently available drugs, which the FDA has said "threatens to erode the progress made in the world-wide control of tuberculosis."

Sirturo is designed to work in a new way to treat tuberculosis and would be used with other drugs.

Shares of J&J rose 27 cents to $69.75.

Write to Joseph Walker at joseph.walker@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
10:47p JOHNSON & JOHNSON : Tech firm seeks $3.3 in tax credits; plans move to R.I.
04:20p JOHNSON & JOHNSON : Wants to Tap Innovators Worldwide to Help Create the Healthi..
03/21 JOHNSON & JOHNSON : Ministry of Health launches Diabetes Early Detection Program..
03/21 JOHNSON & JOHNSON : to Host Investor Conference Call on First-Quarter Results
03/21 JOHNSON & JOHNSON : Global Dental Anesthesia Market Key Players Astra Zeneca, Se..
03/18 JOHNSON & JOHNSON : New Phase 3 Study Finds XARELTO® to Be Superior to Aspirin f..
03/18 JOHNSON & JOHNSON : New Phase 3 Study Finds XARELTO to Be Superior to Aspirin fo..
03/17 JOHNSON & JOHNSON : University of Leicester - Leicester Precision Medicine Insti..
03/17 JOHNSON & JOHNSON : opens regional offices in Ghana and Kenya
03/16 TALCUM POWDER LAWSUIT NEWS : FDA Funds Research to Investigate Ovarian Cancer Ri..
More news
Sector news : Pharmaceuticals - NEC
09:14p MYLAN : recalls 81,000 EpiPens outside U.S. after reports of failure
03/21DJSANOFI'S PRESCRIPTION FOR GROWTH : Drug Sales in the Middle Kingdom
03/20 FTSE rises to record close after Article 50 trigger date set
03/17DJPFIZER : Files 8K - Other Events
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01:14p Wells Fargo sees significant upside in Xarelto sales if use expanded to CV ri..
12:41p WORD ON WALL STREET : Pharma Segment Key To Johnson & Johnson's 2017 Performance
11:42a JOHNSON & JOHNSON : Great Business With A Great Future - A Great Time To Buy?
10:31a 5 Dividend Stocks Expected To Increase Distributions In 2017
08:27a MY 4% DIVIDEND YIELD PORTFOLIO : Q1'17 Summary And Short Term Expectations
Advertisement
Financials ($)
Sales 2017 74 629 M
EBIT 2017 23 135 M
Net income 2017 18 205 M
Finance 2017 22 716 M
Yield 2017 2,63%
P/E ratio 2017 19,11
P/E ratio 2018 17,87
EV / Sales 2017 4,32x
EV / Sales 2018 4,07x
Capitalization 344 961 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 126 $
Spread / Average Target -1,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON10.45%344 961
ROCHE HOLDING LTD.8.81%216 473
PFIZER INC.5.45%203 963
NOVARTIS AG2.09%195 883
MERCK & CO., INC.8.56%175 469
SANOFI7.59%115 573
More Results